title: European best practice guidelines 17-18: adverse effects.
authors.forename: W H
authors.initials: WH
authors.lastname: Hörl
authors.forename: C
authors.initials: C
authors.lastname: Jacobs
authors.forename: I C
authors.initials: IC
authors.lastname: Macdougall
authors.forename: F
authors.initials: F
authors.lastname: Valderrábano
authors.forename: I
authors.initials: I
authors.lastname: Parrondo
authors.forename: B G
authors.initials: BG
authors.lastname: Carveth
authors.forename: K
authors.initials: K
authors.lastname: Thompson
mesh_terms: D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000150:complications / Q000401:mortality; D002408:Catheters, Indwelling / Q000009:adverse effects; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005060:Europe; D006306:Health Surveys; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000401:mortality; D017410:Practice Guidelines as Topic; D016019:Survival Analysis; D013927:Thrombosis / Q000209:etiology
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin